Clinical trials
Phase 2 Anxiety Disorders trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 22 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital, Clermont-Ferrand | 2 |
| Acadia University | 1 |
| CES University | 1 |
| Columbia Northwest Pharmaceuticals | 1 |
| Coordinación de Investigación en Salud, Mexico | 1 |
| Leila Dargahi. PharmD PhD | 1 |
| Medical University of Lodz | 1 |
| Memorial Hermann Health System | 1 |
| National Center for Research Resources (NCRR) | 1 |
| NeuroCognitive and Behavioral Institute Clinical Research Foundation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anxiety Disorders | 22 |
| Parkinson Disease | 3 |
| Stress Disorders, Post-Traumatic | 3 |
| Brain Injuries, Traumatic | 2 |
| Mental Disorders | 2 |
| Acquired Immunodeficiency Syndrome | 1 |
| Alcoholism | 1 |
| Amyotrophic Lateral Sclerosis | 1 |
| Anemia, Sickle Cell | 1 |
| Antisocial Personality Disorder | 1 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.